Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 3 studies described adult participants.

2 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, unknown_unresolved.

Not extracted from the authoritative source.

Available source content was suppressed because validation identified a conflict.

Clinician-reference record is usable with limitations in: comparator.

Patients received insulin glargine in the morning with fixed doses of metformin.

Insulin glargine plus metformin

After 24 weeks, HbA1C levels improved from (mean ± SD) 8.5±0.9% to 7.7±0.8% (69.0±10.0 mmol/mol to 60.8±8.6 mmol/mol) with insulin glargine plus metformin.

Patients received insulin glargine in the morning with fixed doses of glimepiride.

Insulin glargine plus glimepiride

After 24 weeks, HbA1C levels improved from 8.4±1.0% to 7.7±1.3% with insulin glargine plus glimepiride.

Patients received insulin glargine in the morning with fixed doses of both glimepiride and metformin.

Insulin glargine plus glimepiride plus metformin

After 24 weeks, HbA1C levels improved from 8.7±0.9% to 7.3±0.6% with insulin glargine plus glimepiride plus metformin.

Authoritative quality diagnostic: invalid or missing unit.

Authoritative quality diagnostic: invalid or missing value.

Insulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.

Metformin Group

Core clinician-reference fields are available or not applicable.

Patients received a combination of pioglitazone and metformin.

Pioglitazone and Metformin Group

A total of 120 newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease from 8 centers were randomly divided into the control group (metformin hydrochloride) and the test group (pioglitazone hydrochloride and metformin hydrochloride).

Pioglitazone and Metformin Reduce Liver Fat in Diabetes

Patients received 50 mg of vildagliptin orally twice daily.

Vildagliptin Group

The first group (117 patients) received 50 mg of vildagliptin orally twice daily.

Patients received 500 mg of metformin orally twice daily with meals, with dosage adjustable.

The second group (129 patients) received 500 mg of metformin orally twice daily with meals, and the dosage could be gradually increased by 500 mg per week, up to a maximum daily dose of 2000 mg.

Metformin × Body weight

Available supporting studies

Insulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.

Pioglitazone and Metformin Reduce Liver Fat in Diabetes

Vildagliptin and Metformin Improve Glycemic Control in Type 2 Diabetes